BIMI Holdings Inc. BIMI
- Market cap
- $170.0K
- P/E
- 0.0×
Follow BIMI
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 26.05 | 38.00 | 43.00 | 51.50 | 75.00 | 23.60 | 1.07 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | 109.50 | 79.00 | 1,250.00 | 1,035.00 | 370.00 | 140.50 | 27.00 |
High Price
|
|||
| — | — | — | 220 | 220 | 81 | 110 | 222 | 524 | 296 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 6 | 9 | 7 | 0 | 13 | 21 | 12 |
Revenue
|
|||
| — | — | — | 2.46% | 10.77% | 7.02% | (92.47%) | 19.02% | 11.38% | 16.48% |
Gross Margin
|
|||
| — | — | — | (2) | (2) | 0 | (2) | (3) | (35) | (22) |
EBT
|
|||
| — | — | — | (30.08%) | (18.52%) | (3.25%) | (972.15%) | (26.09%) | (162.59%) | (182.77%) |
EBT Margin
|
|||
| — | — | — | (2) | (2) | 0 | (2) | (4) | (35) | (22) |
Net Income
|
|||
| — | — | — | 1 | 1 | 1 | 0 | 2 | 2 | 3 |
Depreciation
|
|||
| — | — | — | 45.94 | 60.13 | 43.76 | 0.97 | 60.16 | 39.78 | 4.44 |
Revenue/Sh
|
|||
| — | — | — | (14.00) | (11.00) | (110.83) | (27.00) | (9.00) | (65.10) | (8.38) |
Earnings/Sh
|
|||
| — | — | — | 1.22 | (6.42) | (2.30) | (12.64) | (16.48) | (8.28) | (3.85) |
Cash Flow/Sh
|
|||
| — | — | — | (3.10) | 0.00 | 0.00 | 0.00 | (15.57) | (0.45) | 0.00 |
Capex/Sh
|
|||
| — | — | — | (1.88) | (6.42) | (2.30) | (12.64) | (32.05) | (8.73) | (3.85) |
Free CF/Sh
|
|||
| — | — | — | 203.10 | 192.91 | 66.79 | 52.10 | 79.13 | 21.15 | 1.96 |
Book Value/Sh
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.95 | 0.86 | 17.97 | 35.38 | 1.39 | 0.64 | 0.31 |
PS Ratio
|
|||
| — | — | — | 0.21 | 0.27 | 11.78 | 3.06 | 1.06 | 1.21 | 0.70 |
PB Ratio
|
|||
| — | — | — | 1.88 | 1.67 | 18.83 | 35.52 | 1.70 | 0.47 | 0.15 |
EV/Sales
|
|||
| — | — | — | 7.51 | (10.85) | (363.75) | (13.04) | (3.21) | (2.13) | (0.17) |
EV/FCF
|
|||
| — | — | — | 0 | (1) | 0 | (2) | (4) | (4) | (10) |
Op' Cash Flow
|
|||
| — | — | — | 0 | — | — | — | (3) | 0 | — |
Capex
|
|||
| — | — | — | 0 | (1) | 0 | (2) | (7) | (5) | (10) |
FCF
|
|||
| — | — | — | 5 | 5 | 10 | 9 | 10 | (1) | (2) |
Working Cap'
|
|||
| — | — | — | 6 | 7 | 6 | 0 | 4 | 1 | 0 |
Total Debt
|
|||
| — | — | — | 6 | 7 | 6 | 0 | 4 | (4) | (2) |
Net Debt
|
|||
| — | — | — | 27 | 27 | 10 | 9 | 17 | 11 | 5 |
Sh' Equity
|
|||
| — | — | — | (4.45%) | (3.99%) | (52.06%) | (16.71%) | (6.31%) | (98.10%) | (60.65%) |
ROA
|
|||
| — | — | — | (2.86%) | (2.18%) | (0.85%) | (7.15%) | (11.43%) | (261.26%) | (290.38%) |
ROIC
|
|||
| — | — | — | (6.37%) | (5.81%) | (90.05%) | (47.99%) | (15.72%) | (247.86%) | (270.56%) |
ROE
|
|||
BIMI Holdings Inc. peers in Pharmaceutical Retailers
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MDVLQ MedAvail Holdings, Inc. | $2.9M | 0.0× | Compare |
| RDGT Ridgetech Inc. | $3.3M | 0.0× | Compare |
| POM Pomdoctor Limited - Sponsored ADR | $7.8M | — | Compare |
| MEDS DataMeds AI, Inc | $10.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SCNX Scienture Holdings, Inc. | $12.3M | 0.0× | Compare |
| PETS PetMed Express, Inc. | $33.7M | 0.0× | Compare |
| HITI High Tide Inc. | $240.2M | 0.0× | Compare |
BIMI Holdings Inc. (BIMI) Latest News
20 May
BIMI Holdings Inc. received a delinquency compliance alert notice from Nasdaq due to failure to file required reports with the SEC. The delinquency notice may moderately influence BIMI's financial performance and competitive positioning.
23 Apr
BIMI Holdings Inc. received a delinquency compliance alert notice from Nasdaq due to failure to file annual report on time. The delinquency notice may moderately impact BIMI's financial performance and competitive positioning.
3 Jan
BIMI Holdings Inc. announced results of 2023 Annual General Meeting of Stockholders. The outcomes of the meeting, such as board composition changes and executive compensation approval, may moderately influence the company's future performance.
19 Dec
BIMI International Medical Inc. reported financial results for Q3 2023, showing a decrease in revenues and net loss compared to the previous year. The financial results may moderately influence BIMI's financial performance and competitive positioning.
28 Nov
BIMI International Medical Inc. announced buyback of warrants totaling $2,120,073.80. The buyback of warrants could have a moderately noticeable influence on BIMI's financial performance and competitive positioning.
27 Nov
BIMI International Medical Inc. reported increased revenues and gross margins for the second quarter of 2023. The financial results and acquisition of Phenix Bio Inc. are expected to significantly impact BIMI's future performance.
BIMI received a Nasdaq notification of non-compliance for failing to file required financial reports. The non-compliance with Nasdaq listing rules may moderately affect the company's financial performance and market sentiment.
8 Nov
Phenix Bio Inc., a subsidiary of BIMI, launches CUCA 3.0 Product Line through China Duty Free Group's online platform. The launch of a new product line through a major retail platform like CDFG is a significant move that could have a major impact on BIMI's future performance and market positioning.
30 Oct
BIMI International Medical Inc. appoints Hao Mu Pte. Ltd. as distributor for herbal supplements in Mainland China. The appointment of a distributor in Mainland China is a significant move that can impact BIMI's future market performance.
BIMI International Medical Inc. appoints exclusive distributor for herbal supplements in Hong Kong, Taiwan, and Macau. The appointment of an exclusive distributor in key territories may moderately influence BIMI's market performance and expansion strategy.
22 Sep
Phenix Bio Inc., a subsidiary of BIMI International Medical Inc., appoints exclusive distributor for ASEAN countries. The exclusive distributor appointment in ASEAN countries is a significant strategic move that can impact BIMI's market reach and revenue potential.
7 Aug
BIMI International Medical Inc. partners with China Duty Free Group to distribute healthcare products in China. The strategic partnership with CDFG is a significant move that can expand BIMI's footprint in the Asian market.
22 May
BIMI International Medical Inc. reported improved financial results for the first quarter of 2023, with increased revenues and decreased net losses. The financial improvements are expected to moderately influence the company's performance and competitive positioning.
6 May
BIMI International Medical reported a net loss of US$21.7m for FY 2022, with revenue down 56% to US$11.8m. The financial results show a moderately noticeable influence on the company's performance.